DCT

2:26-cv-03509

Ultragenyx Pharmaceutical Inc v. Somerset Therap LLC

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:

  • Case Identification: 2:26-cv-03509, D.N.J., 04/01/2026

  • Venue Allegations: Venue is alleged to be proper in the District of New Jersey because the Defendant entities maintain a regular and established place of business in the district and have committed acts of infringement there, including the submission of the Abbreviated New Drug Application (ANDA) from their New Jersey place of business.

  • Core Dispute: Plaintiffs allege that Defendants' filing of an ANDA to market a generic version of Plaintiffs' Dojolvi® (triheptanoin) oral liquid constitutes an act of patent infringement of two U.S. patents covering the drug composition and its method of use.

  • Technical Context: The technology concerns pharmaceutical-grade triheptanoin, an odd-carbon medium-chain triglyceride, used as a medical food for treating rare, genetic long-chain fatty acid oxidation disorders (LC-FAOD).

  • Key Procedural History: The lawsuit was initiated under the Hatch-Waxman Act following Defendants' submission of an ANDA with a Paragraph IV certification to the FDA. The certification asserts that the patents-in-suit are invalid, unenforceable, and/or will not be infringed by the proposed generic product. The complaint was filed within the 45-day statutory window, triggering an automatic 30-month stay of FDA approval for the Defendants' generic product.

Case Timeline

Date Event
2004-07-02 U.S. Patent No. 8,697,748 Priority Date
2013-11-14 U.S. Patent No. 12,551,461 Priority Date
2014-04-15 U.S. Patent No. 8,697,748 Issues
2026-02-17 U.S. Patent No. 12551461 Issues
2026-02-18 Somerset sends Paragraph IV Notice Letter to Plaintiffs
2026-02-19 Plaintiffs submit '461 Patent for Orange Book listing
2026-04-01 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 8,697,748

  • Patent Identification: U.S. Patent No. 8,697,748, "Glycogen or polysaccharide storage disease treatment method," issued April 15, 2014 (the "'748 Patent").

The Invention Explained

  • Problem Addressed: The patent's background describes genetic disorders like Glycogen-storage disease type II (GSD II or Pompe's disease), where a deficiency in a specific enzyme leads to the abnormal accumulation of glycogen in cells Compl., Ex. A, '748 Patent, col. 1:24-30 This accumulation disrupts normal cellular function, causing progressive muscle weakness and organ damage, for which existing treatments offer limited relief Compl., Ex. A, '748 Patent, col. 2:5-23
  • The Patented Solution: The invention proposes a metabolic therapy using odd-carbon fatty acids, such as triheptanoin, as an alternative energy source for patients Compl., Ex. A, '748 Patent, abstract When metabolized, these compounds provide intermediates for the Citric Acid Cycle (the cell's primary energy-producing pathway), thereby bypassing the defective glycogen metabolism pathway and supplying cells with needed energy Compl., Ex. A, '748 Patent, col. 2:50-54 This therapeutic approach is illustrated conceptually in the patent's Figure 4 Compl., Ex. A, '748 Patent, Fig. 4
  • Technical Importance: This approach offers a novel therapeutic strategy that addresses the downstream energy deficit in certain metabolic disorders, serving as a potential alternative or complement to treatments like enzyme replacement therapy Compl. ¶15

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶58
  • The essential elements of Claim 1 are:
    • A composition comprising an active agent.
    • The active agent consists essentially of a triheptanoin.
    • The composition has an acid value of 0.1 or less mg KOH/gr.
    • The composition has a hydroxyl value of 2.8 or less mg KOH/gr.
  • The complaint does not explicitly reserve the right to assert dependent claims but alleges infringement of "one or more claims" Compl. ¶58

U.S. Patent No. 12,551,461

  • Patent Identification: U.S. Patent No. 12,551,461, "Compositions of triglycerides and uses thereof," issued February 17, 2026 (the "'461 Patent").

The Invention Explained

  • Problem Addressed: The patent background describes practical challenges associated with the drug triheptanoin's natural form as an oil Compl., Ex. B, '461 Patent, col. 1:25-28 The liquid formulation is described as difficult to administer due to poor miscibility with food and drink, and can cause significant gastrointestinal side effects such as gastric upset, spasms, and diarrhea, which can limit the tolerable dose Compl., Ex. B, '461 Patent, col. 1:30-45
  • The Patented Solution: The invention is directed to improved compositions of triglycerides. While much of the specification discusses formulating the oily drug into a solid powder by adsorbing it onto a solid substance like fumed silica, the claims cover specific liquid compositions with high purity Compl., Ex. B, '461 Patent, abstract Compl., Ex. B, '461 Patent, col. 1:52-58 Compl., Ex. B, '461 Patent, claim 1 The solid formulation aims to be easier to handle and administer, with the potential for delayed release to improve gastrointestinal tolerability Compl., Ex. B, '461 Patent, col. 7:25-48
  • Technical Importance: By defining specific high-purity compositions, the invention seeks to provide a more consistent and potentially safer product, while the development of a solid dosage form addresses formulation challenges to improve patient compliance and enable more effective dosing regimens Compl., Ex. B, '461 Patent, col. 7:48-54

Key Claims at a Glance

  • The complaint asserts at least independent claim 1 Compl. ¶67
  • The essential elements of Claim 1 are:
    • A pharmaceutical composition comprising an active ingredient, diheptanoate, and hexano-diheptanoate.
    • The active ingredient is in the form of triheptanoin oil with a purity greater than 98%.
    • The composition comprises 0.01% to 1.5% diheptanoate by weight.
    • The composition comprises 0.01% to 1.0% hexano-diheptanoate by weight.
    • Glycerol is undetectable in the composition.
    • Monoheptanoate is undetectable in the composition.
    • The composition comprises no more than 0.2% water by weight.
    • The composition is a liquid composition for oral administration to a human.
  • The complaint alleges infringement of "one or more claims" of the patent Compl. ¶67

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is "Somerset's ANDA Product," a proposed generic version of Dojolvi® (triheptanoin) Oral Liquid, 100% w/w, identified in ANDA No. 221271 Compl. ¶1

Functionality and Market Context

  • The product is an oral liquid formulation of triheptanoin intended for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD) Compl. ¶15 Compl. ¶46
  • By filing its ANDA, Somerset has represented to the FDA that its product is bioequivalent to the reference listed drug, Dojolvi®, meaning it is intended to have the same active ingredient, dosage form, strength, and route of administration Compl. ¶48 The complaint alleges that upon approval, the Defendants intend to commercially manufacture, market, and sell this product in the United States Compl. ¶1 Compl. ¶53

IV. Analysis of Infringement Allegations

No probative visual evidence provided in complaint.

The complaint does not contain detailed infringement allegations or claim charts. The infringement theory is based on the premise that the Defendants' product, being a generic copy of Dojolvi® intended to be bioequivalent, will necessarily meet the limitations of the asserted claims covering the Dojolvi® product.

'748 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A composition comprising an active agent, wherein the active agent consists essentially of a triheptanoin... Somerset's ANDA Product is an oral liquid whose active ingredient is triheptanoin Compl. ¶47 ¶47 col. 37:1-3
...and wherein the composition has an acid value of 0.1 or less mg KOH/gr, a hydroxyl value of 2.8 or less mg KOH/gr. The complaint does not allege specific values for Somerset's product. Infringement is premised on the ANDA product being a generic equivalent of Dojolvi®, which is covered by the patent, and therefore is alleged to meet these purity specifications Compl. ¶1 Compl. ¶48 Compl. ¶58 The precise specifications are contained in the confidential ANDA. ¶48; ¶58 col. 37:4-6

'461 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A pharmaceutical composition comprising an active ingredient, diheptanoate, and hexano-diheptanoate, wherein the active ingredient is in the form of triheptanoin oil; wherein the triheptanoin oil has a purity greater than 98%... Somerset's ANDA Product is a triheptanoin oral liquid Compl. ¶47 The complaint alleges that as a generic equivalent of Dojolvi®, it will meet the purity limitation of the branded product Compl. ¶48 Compl. ¶67 ¶47; ¶67 col. 26:40-44
...wherein the composition comprises 0.01% to 1.5% diheptanoate by weight; wherein the composition comprises 0.01% to 1.0% hexano-diheptanoate by weight... The complaint does not provide specific impurity profiles. The infringement allegation is based on the premise that Somerset's product, as a generic, will have an impurity profile that falls within the claimed ranges Compl. ¶48 Compl. ¶67 ¶67 col. 26:46-49
...wherein glycerol is undetectable in the composition; wherein monoheptanoate is undetectable in the composition... The complaint does not specify whether these impurities are present in Somerset's product. This determination will depend on the specifications within the confidential ANDA and the analytical methods used for detection Compl. ¶67 ¶67 col. 26:50-52
...wherein the composition comprises no more than 0.2% water by weight; and wherein the composition is a liquid composition for oral administration to a human. Somerset's ANDA Product is described as a "triheptanoin oral liquid" Compl. ¶47 The complaint alleges that this product will meet the water content limitation as part of being a generic equivalent Compl. ¶48 Compl. ¶67 ¶47; ¶67 col. 26:53-56
  • Identified Points of Contention:
    • Factual Questions: The primary dispute will be factual, centering on the precise chemical specifications of the product described in Somerset's confidential ANDA. The case will require discovery into whether Somerset's product meets the specific purity parameters (e.g., acid value, hydroxyl value, >98% purity) and impurity profiles (e.g., ranges for diheptanoate/hexano-diheptanoate, absence of glycerol/monoheptanoate) recited in the claims.
    • Scope Questions: For the '748 Patent, a question may arise over the scope of "consists essentially of." The analysis will question whether any unlisted ingredients in Somerset's formulation materially alter the basic and novel properties of the claimed triheptanoin composition. For the '461 Patent, a central question will be the proper construction of "undetectable," as this will define the boundary for the absence of glycerol and monoheptanoate.

V. Key Claim Terms for Construction

  • The Term: "consists essentially of" (from '748 Patent, Claim 1)

    • Context and Importance: This transitional phrase is narrower than "comprising" but broader than "consisting of." It allows for the presence of unlisted components that do not materially affect the "basic and novel properties" of the invention. Practitioners may focus on this term because the dispute will center on whether excipients or other impurities in Somerset's ANDA product materially affect the therapeutic properties of the triheptanoin composition as envisioned by the patent.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The patent specification broadly describes the invention as a method of treating glycogen storage disease by administering an effective amount of a composition that includes ketogenic odd carbon fatty acids to ameliorate symptoms Compl., Ex. A, '748 Patent, abstract This focus on the metabolic effect could support an interpretation where any component not interfering with that metabolic function is permitted.
      • Evidence for a Narrower Interpretation: The claim itself recites specific purity values (acid and hydroxyl values). This may support an argument that the "basic and novel properties" are tied to this high level of purity, and any additional component that alters this purity profile, even slightly, would be a material change.

  • The Term: "undetectable" (from '461 Patent, Claim 1)

    • Context and Importance: The scope of this term is critical for determining infringement, as it sets the threshold for the absence of glycerol and monoheptanoate. The definition is not absolute and depends on the sensitivity of the analytical method used. Practitioners may focus on this term because infringement could hinge entirely on whether the analytical method used by Somerset's experts can detect trace amounts of these impurities that another method could not.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation (i.e., less sensitive standard): A party could argue that the term should be interpreted in the context of standard quality control methods available to a person of ordinary skill in the art at the time, rather than the most sensitive, cutting-edge laboratory technique, unless the patent specifies such a technique.
      • Evidence for a Narrower Interpretation (i.e., more sensitive standard): The specification provides tables showing analytical results where certain impurities are listed as "not detectable" Compl., Ex. B, '461 Patent, Table 4 The methods used are cited as "Ph. Eur." (European Pharmacopoeia) Compl., Ex. B, '461 Patent, Table 2 This evidence suggests that "undetectable" should be defined by the limits of the specific pharmacopoeia-standardized methods referenced in the patent's own examples.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that upon FDA approval, Somerset will induce infringement by encouraging doctors and patients to use its generic product in an infringing manner, and will contributorily infringe by selling a product especially adapted for an infringing use with no substantial non-infringing use Compl. ¶¶59-60 Compl. ¶¶68-69
  • Willful Infringement: The complaint alleges that Somerset had knowledge of the patents-in-suit via their listing in the FDA's Orange Book and through the Paragraph IV notice letter sent to the Plaintiffs, and that any subsequent infringement upon commercial launch would be willful Compl. ¶45 Compl. ¶49 Compl., Prayer for Relief (g)

VII. Analyst's Conclusion: Key Questions for the Case

  1. A central issue will be one of evidentiary proof: Will discovery of Somerset's confidential ANDA reveal a product specification that falls squarely within the precise purity and impurity limitations recited in the asserted claims of both the '748 and '461 patents? The outcome will likely depend on a direct comparison of analytical data.
  2. A key question of claim construction will be the definition of "undetectable" in the '461 patent. The case may turn on whether this term is defined by a general standard of analytical chemistry or by the specific European Pharmacopoeia methods referenced in the patent's own examples, which could significantly narrow or broaden the claim's scope.
  3. A third major component of the case will be the validity challenge: Can Somerset prove by clear and convincing evidence that the asserted claims are invalid as anticipated or obvious in light of prior art relating to triheptanoin compositions, as asserted in its Paragraph IV certification?
Loading Complaint